Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2

Status

Unknown 2Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 5

Study Type

Interventional 8

Sponsor

Cancer Type

Genitourinary 39Gastrointestinal 24Breast 13Dermatologic 10Thoracic 9Head & Neck 9Tumor-Agnostic 8Gynecologic 8Lymphoid 7Sarcoma 6Endocrine 6CNS 6Other hematologic neoplasm 5Other solid neoplasm 4NET 4

Conditions

Neoplasms 3Neoplasm Metastasis 3Neoplasms, Second Primary 1Carcinoma 1Adenocarcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
OTHER × avelumab × Tumor-Agnostic × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT04266912 2025-11-25

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
23 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Ludwig-Maximilians - University of Munich

Phase 2 Completed
57 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Johannes Gutenberg University Mainz

Phase 2 Unknown
30 enrolled
Tumor-Agnostic

Neoplasms

NCT03891238 2024-02-01

ARIES

Consorzio Oncotech

Phase 2 Completed
67 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03000179 2022-04-14

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

Vanderbilt-Ingram Cancer Center

Phase 2 Terminated
8 enrolled 12 charts
Tumor-Agnostic

Adenocarcinoma

NCT04698213 2021-01-06

TIDE-A

Consorzio Oncotech

Phase 2 Unknown
75 enrolled
Tumor-Agnostic

Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡